Affordable Access

Publisher Website

Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans

Authors
Journal
Vaccine
0264-410X
Publisher
Elsevier
Publication Date
Volume
25
Identifiers
DOI: 10.1016/j.vaccine.2007.07.014
Keywords
  • Transcutaneous Administration
  • Measles Virus
  • Vaccines
  • Iga
Disciplines
  • Medicine

Abstract

Abstract Transcutaneous immunisation (TCI) using a skin patch is a non-invasive vaccination route relevant to mass vaccination against infectious diseases. This phase I/II clinical study, documents that TCI of human adult volunteers with the live-attenuated measles vaccine ROUVAX ® is safe and poorly reactogenic. It promotes induction of measles-specific salivary IgA and a tendency to increased frequency of MV-specific IFNγ-producing T cells. However, in contrast to the subcutaneous route, TCI failed to evoke neutralising MV-specific serum antibodies. Thus, alternative delivery methods and/or devices providing optimal uptake by skin DC should be considered for live-attenuated virus vaccines, such as the measles vaccine.

There are no comments yet on this publication. Be the first to share your thoughts.